The effects of chronic use of antipsychotics on the bone, breast, and cervix;Kronik antipsikotik kullanımının kemik, meme ve serviks üzerine etkileri

Klinik Psikofarmakoloji Bulteni

Volumn 21, Issue 2, 2011, Pages 114-121

  Bilici, Mustafa ^a   Yenel, Aynil ^a   Kavlak, Sibel Ödemiş ^a   Uz, Yasemin ^a   Sünbül, Esra Aydin ^a   Çiftçi, Aylin ^b  

^a stanbul Erenköy Ruh ve Sinir Hastal klar E itim ve Ara t rma Hastanesi   (Turkey)

^b Belediyesi Kadin Sa li i Merkezi   (Turkey)

Author keywords

Antipsychotic; Bone mineral density; Breast cancer; Cervical cancer; Osteoporosis

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE; BONE MINERAL; BREAST; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; MICROSCOPY; OSTEOPOROSIS; PROLACTIN BLOOD LEVEL; RADIOLOGY; UTERINE CERVIX; UTERINE CERVIX CANCER;

EID: 79961095150     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20110510114010     Document Type: Article

References (34)

1. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. Journal of Clinical Psychiatry, 2004; 65(12): 1607-1618
2. Bilici M, Cakirbay H, Guler M. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. International Journal of Neuroscience, 2002; 112(7): 817-818
3. Jung DU, Conley RR, Kelly DL. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 2006; 67(9):1391-1396
4. Volavka J, Czobor P, Sheitman B. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry, 2002;159(2): 255-262
5. Klibanski A, Neer R, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980; 303(6):1511-1514
6. Biller BMK, Baum HBA, Rosenthal DI. Progressive trabecular osteopenia in women with hyperprolactine amenorrhea. J Clin Endocrinol Metab, 1992;75(3):692-697
7. Howes OD, Wheeler MJ, Meaney AM. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J. Clin Psychopharmacol, 2005; 25 (3): 259-261
8. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R. et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatr, 2002; 59(12): 1147-1154
9. Grinshpoon A, Barchana M, Ponizovsky A, Cancer in schizophrenia: is the risk higher or lower? Schizophrenia Research, 2005; 73(2-3): 333-341
10. Dalton SO, Johansen C, Poulsen AH, Norgaard M, Sorensen HT, McLaughlin JK et al. Cancer Research UK Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer. 2006; 95(7): 934-939,
11. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, Yuan HJ, DeVane CL. Antipsychotic Drugs Inhibit the Function of Breast Cancer Resistance Protein. Basic & Clinical Pharmacology & Toxicology, 2008;103:(4):336-341
12. Tilbrook D, Polsky J, Lofters AM, Are women with psychosis receiving adequate cervical cancer screening. Can Fam Physician, 2010;56(4):358-3363
13. First MB, Spitzer RL, Gibbon M. Structed Clinical interview for DSM IV Axis Disorders (SCID-1) Clinical version. Washington D.C. and London: American Psychiatric Pres. 1997
14. Çorapçioǧlu A, Aydemir Ö, Yildiz M ve ark. DSM IV Eksen 1 bozukluklari{dotless} (SCID-1) için yapi{dotless}landi{dotless}ri{dotless}lmi{dotless}ş klinik görüşme, Klinik versiyon. Ankara: Hekimler Yayi{dotless}n Birliǧi; 1999
15. Sapin R, Simon C. Inc. False Hyperprolactinemia Corrected by the Use of Heterophilic Antibody-blocking Agent. American Association for Clinical Chemistry, 2001; 47(12):2184-2185
16. Barthe N, Braillon P, Ducassou D, Basse-Cathalinat B. Comparison of two Hologic DXA systems (QDR 1000 and QDR 4500/A). The British Journal of Radiology, 1997; 70(835):728-739
17. Kleerekoper M, Gold DT. Osteoporosis prevention and management: an evidence-based review. Clin Obstet Gynecol, 2008;51(3):556-563
18. Yilmaz MH. Meme Kanserinde Radyolojik Tani{dotless} ve Deǧerlendirme. Meme Kanseri Sempozyum Dizisi No: 54, Arali{dotless}k 2006; s. 27-30
19. Seçkin C.N, Turhan NÖ, Özmen Ş, Avşar F, Ersan F, Erdoǧan M. et al. Benign Atipik Servikal Smear'li Hastalari{dotless}n Rutin Kolposkopik İnceleme ve Biopsi Sonuçlari{dotless}. T Klin Jinekol Obst, 1996; 6(2): 173-175
20. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry, 2006;67(9):1470
21. Kurt E, Emül HM, Oral ET. Yeni antipsikotikler ve haloperidolün PRL üzerindeki etkilerinin karşi{dotless}laşti{dotless}ri{dotless}lmasi{dotless}. Anadolu Psikiyatri Dergisi, 2008; 9(1):44-8
22. Klibansky A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur J W. Decreased bone density in hyperprolactinemic women. N. Engl. J. Med.,1980; 303(3):1511-1514
23. Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med, 1986; 104(6):777-782
24. Altindaǧ Ö, Altindaǧ A, Virit O, Savaş HA, Yilmaz M, Bozgeyik Ö. et al. Antipsikotik ilaç kullanan şizofreni hastalari{dotless}nda kemik mineral yoǧunluǧu. Klinik Psikofarmakoloji Bülteni, 2009; 19(4):402-406
25. Abraham G, Paing W, Kaminski J, Joseph A, Kohegyi E, Josiassen RC. Effects of Elevated Serum Prolactin on Bone Mineral Density and Bone Metabolism in Female Patients With Schizophrenia: A Prospective Study. Am J Psychiatry 2003; 160(9):1618-1620
26. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G, Naveda RCM. et al. Osteoporosis in Patients With Schizophrenia. Am J Psychiatry 2005;162(1):162-167
27. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 2002; 359:1929-1936
28. Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Phamacol, 1999; 58(8): 1229-1236
29. Overall JE. Prior psychiatric treatment and the development of breast cancer. Arch Gen Psychiatr, 1978; 35(7): 898-899
30. Wagner S, Mantel N. Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents. Cancer Res, 1978; 38(9):2703-2708.
31. Kanhouwa S, Gowdy JM, Solomon JD. Phenothiazines and breast cancer. J Natl Med Ass, 1984; 76(8): 785-788
32. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD. et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol, 1999; 150(8): 861-868
33. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R et al. Avorn J. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatr, 2002; 59(12):1147-1154
34. Collins Y, Downs LS Jr, Scarinci I, Einstein MH, Flowers L. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol, 2010;117(3):486-490